Debiopharm and Aurigene Sign Agreement for the Development and Commercialization of Debio 1142
Complete the form below to unlock access to ALL audio articles.
Debiopharm Group™, and Aurigene Discovery Technologies Ltd have signed on March 23, 2011 an option and exclusive worldwide license agreement concerning the development and commercialization of Debio 1142, a novel inhibitor of an undisclosed oncology pathway.
“We are very excited about this new collaboration with Aurigene. Their business model offers a one stop solution for structure guided drug design, lead optimization and preclinical work. The Debio 1142 project aims at developing inhibitors targeting a key oncology pathway, which plays essential roles in various solid tumours, including resistance to chemotherapy” said Dr Rolland-Yves Mauvernay, president and founder of Debiopharm S.A.
“Coming as it does after a successful collaboration programme we already had with Debiopharm, and as a continuation of our close to 5 year association, the relationship between Debiopharm and Aurigene demonstrates the strategic fit between organizations with complimentary scientific skills. We are happy that we have the opportunity to continue to work with Debiopharm, in a unique business model that has been tailor-made to meet each partners’ needs” added CSN Murthy, CEO of Aurigene.